Abstract

Purpose To assess usefulness of adding contrast-enhanced ultrasonography (CEUS) to fusion imaging (FI) for percutaneous radiofrequency ablation (RFA) of hepatocellular carcinomas (HCCs) inconspicuous on FI alone. Therapeutic outcomes of RFA under CEUS-added FI guidance for HCCs inconspicuous on FI alone were also evaluated. Methods This prospective study was approved by the institutional review board and informed consent was obtained from all patients. Planning US was performed with FI for 126 patients with a single HCC (1–2 cm) to evaluate the feasibility of RFA by grading lesion conspicuity score using a four-point scale. RFA was performed under CEUS-added FI guidance for HCCs inconspicuous on FI alone. We evaluated how many HCCs initially inconspicuous on FI became conspicuous after adding CEUS. After CEUS-added FI-guided RFA, therapeutic outcomes including rates of technical success, primary technique efficacy, major complications, and local tumor progression were assessed. Results After adding CEUS, 90.5% (19/21) of all tumors initially inconspicuous on FI became conspicuous, thus enabling direct targeting for RFA. Technical success and primary technique efficacy rates were 94.7% (18/19) and 100% (19/19), respectively. No major complications were observed after RFA. Cumulative local tumor progression rates after RFA were estimated to be 5.3%, 10.8%, and 10.8% at 1, 2, and 3 years, respectively. Conclusion Adding CEUS to FI is useful for improving the conspicuity of HCCs inconspicuous on FI alone, thus enabling successful percutaneous RFA with excellent therapeutic outcomes.

Highlights

  • It can be challenging to ablate small hepatocellular carcinomas (HCCs) under B-mode ultrasonography (US) guidance as small HCCs sometimes have poor sonographic conspicuity [1]

  • Fusion imaging (FI) can enhance the detectability of small HCCs inconspicuous on B-mode US and reduce false-positive

  • Arrowheads indicate a previous radiofrequency ablation (RFA) zone (b) After fusion imaging, the HCC nodule could not be identified on B-mode US imaging at the corresponding site on fused magnetic resonance imaging (MRI)

Read more

Summary

Introduction

It can be challenging to ablate small hepatocellular carcinomas (HCCs) under B-mode ultrasonography (US) guidance as small HCCs sometimes have poor sonographic conspicuity [1]. Fusion imaging (FI) of B-mode US and pre-acquired computed tomography (CT)/magnetic resonance imaging (MRI) has emerged as a useful guidance modality for percutaneous radiofrequency ablation (RFA) of small HCCs [2,3,4,5]. When a tumor is completely isoechoic compared to surrounding normal liver, FI can only estimate the location of what is in essence a “virtual target,” and incomplete ablation can occur even after FI-guided RFA [6]. This shortcoming is due to the inherent registration error that occurs when applying rigid registration to a deformable organ during motion.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call